Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the therapeutic efficacy of inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (PAP) due to partial dysfunction of the GM-CSF receptor.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01511068
Study type Interventional
Source Children's Hospital Medical Center, Cincinnati
Contact
Status Completed
Phase Phase 2
Start date August 2012
Completion date July 2014

See also
  Status Clinical Trial Phase
Recruiting NCT05761899 - Safety and Efficacy of PMT Therapy of hPAP Phase 1/Phase 2